Cancer
ELAINE 3
Breast Cancer
Phase 3 open label study comparing efficacy and safety of the combination of lasofoxifene and abemaciclib to the combination of fulvestrant and abemaciclib for the treatment of adults with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation
Contact Research Team:
[email protected]
Site principal investigator:
Timothy Pluard, MD
Learn more about this study:
NCT05696626